乳腺癌术后辅助内分泌治疗与糖尿病关系研究进展

Research progress on correlation between postoperative adjuvant endocrine therapy and diabetes mellitus in breast cancer

乳腺癌和糖尿病是女性患者中常见的慢性病,同样威胁着广大女性的生命健康,二者之间的关系也日益受到重视。研究发现乳腺癌采用内分泌药物治疗,他莫昔芬或芳香化酶抑制剂(AIs)可增加患者罹患糖尿病风险,可能与患者使用内分泌药物治疗后体内雌激素水平变化有关,但精准的生物学机制尚不清楚。因此,乳腺癌患者使用内分泌药物治疗期间加强对血糖变化的监测是有必要的,有助于更好的指导临床治疗,提高患者生存质量,延长患者生存期。

Breast cancer and diabetes are common chronic diseases in women,and threaten the health of women,therefore,the correlation between them is also receiving increasing attention.A study have found that breast cancer hormone thereapy of tamoxifen or Aromatase inhibitors(AIs) can increase the risk of diabetes in breast cancer survivor,which may related to change in vivo estrogen level in survivor after hormonr therepy.However,the precise biological mechanism is still unclear.So it is necessary to strengthen the monitoring of blood glucose changes during the treatment of breast cancer patients with endocrine drugs,which will help to better guide clinical treatment,improve the quality of life of patients and prolong the survival of patients.